secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001493152-22-031599
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Q3 net loss $9.5M; Phase 3 EB-101 meets endpoints, BLA submission planned Q2 2023
--------------------------------------------------------------------------------

- Net loss of $9.5M ($1.48 loss per share) for Q3 2022, compared to $7.0M loss in Q3 2021.
- Cash, equivalents and investments totaled $23.5M at Sept 30, 2022; subsequent $35M private placement extends runway into Q3 2024.
- Phase 3 VIITAL trial of EB-101 for RDEB met both co-primary endpoints with statistically significant wound healing and pain reduction.
- Company plans to submit BLA to FDA for EB-101 in Q2 2023; possible Priority Review Voucher eligibility upon approval.
- R&D expenses decreased to $5.5M from $9.1M year-over-year; G&A expenses down to $3.9M from $5.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315222031599/0001493152-22-031599-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315222031599/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031599

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer